ALIVUS
LIFE SCIENCES
Evolve every day

July 30, 2026

To,	**To,**
Dy. General Manager	**The Manager – Listing,**
Department of Corporate Services,	**National Stock Exchange of India Ltd.,**
BSE Ltd.,	**Plot No. C/1, G Block,**
P. J. Towers, Dalal Street,	**Bandra Kurla Complex,**
Fort, Mumbai – 400 001	**Bandra (E), Mumbai – 400 051**
Ref: Scrip Code: 543322	**Ref: Scrip Name: ALIVUS**

Dear Sirs,

Sub: Press Release

Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Press Release of the Company for the First Quarter ended June 30, 2026.

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

RUDALF JOSEPH CORRIEA
Digitally signed by RUDALF JOSEPH CORRIEA
Date: 2026.07.30 18:55:09 +05'30'

Rudalf Correia
Company Secretary and Compliance Officer
Encl.: As above

PRESS RELEASE
For Immediate dissemination

Alivus Life Sciences records highest-ever PAT with growth of 32% YoY and margins at 25%

Revenue growth of 6.4% YoY for Q1FY27

Mumbai, July 30, 2026: Alivus Life Sciences Limited (*formerly Glenmark Life Sciences Limited*), a leading developer and manufacturer of select, high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, today announced its financial results for the quarter ended June 30, 2026.

Revenue from operations for Q1FY27 were at Rs. 6,404 Mn, a growth of 6.4% YoY, driven by robust performance in the non-GPL business, which grew at 26.5% YoY

EBITDA for Q1FY27 stood at Rs. 2,341 Mn, a growth of 29.1% YoY with margins at 36.6%, accelerated by favourable product mix, successful new launches, and the benefits of operating leverage

PAT for Q1FY27 stood at Rs. 1,601 Mn, a growth of 31.8% YoY. PAT margins were at 25.0%, up 480 bps YoY

During Q1FY27, the company generated a strong free cash flow of Rs. 901 Mn, leading to Cash and Cash Equivalents (including short-term investments) of Rs. 8,802 Mn as of June 30, 2026

Commenting on the company's performance Dr. Yasir Rawjee, MD & CEO, Alivus Life Sciences Limited said, *"We are pleased to begin the first quarter of FY27 on a positive note demonstrating the resilience of our business model, strong execution and accelerating traction in the non-GPL business. With recently launched products continuing to gain scale across geographies, we remain confident in the sustainability of this momentum.*

GPL business is expected to be flattish in FY27, despite a significant decline in Q1FY27. GPL business has historically been skewed towards H2 and the same is expected in FY27 as well.

With a continued strong growth momentum in the non-GPL portfolio and muted growth in the GPL business, we remain confident of achieving revenue growth of 10% - 12% in FY27, while sustaining EBITDA margins in the 30%–32% range. At the same time, our ongoing investments in capacity expansion and pipeline development are strengthening the foundation for future growth."

Tushar Mistry, CFO, Alivus Life Sciences Limited said, *"We delivered a strong set of results this quarter, achieving our highest-ever EBITDA margin of 36.6%, reflecting the strength of our portfolio, disciplined execution, and continued focus on operational excellence. A favourable product mix, successful new product launches, and the benefits of operating leverage collectively drove the profitability higher.*

Our strong operating performance was complemented by a healthy balance sheet. We remained a net debt-free company. As on June 30, 2026, we hold cash and cash equivalents of Rs. 8,802 million, providing significant financial flexibility and a strong foundation to invest in future growth opportunities while continuing to create long-term value."

Additional Highlights:

- DMF / CEP filings continue across major markets, taking the total cumulative filings to 617 as on June 30, 2026.
- The HP API portfolio has 29 APIs in the active grid with 13 products validated, seven products in advanced stages of development and the remaining nine products progressing through lab development stages.

Capex Update:

- Solapur – Construction work for Phase 1 (350 KL capacity) and Phase 2 (115 KL capacity) is underway and is expected to be completed in Q3 FY27 and Q4 FY27, respectively.

- Construction has begun for the new R&D facility in Taloja (Navi Mumbai) to establish a state-of-the-art R&D centre. The centre will focus on flow chemistry, complex products, particle engineering, oncology research and green chemistry, strengthening the pipeline across key therapeutic areas.

About Alivus Life Sciences Ltd (ALIVUS)

Alivus Life Sciences Limited (Formerly Glenmark Life Sciences Limited) (BSE: 543322, NSE: ALIVUS), is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. The company is increasingly providing CDMO services to a range of multinational and specialty pharmaceutical companies. It has a diversified portfolio of 181 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).

The company's four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of 1424 KL, which are regularly inspected by global regulators such as USFDA, PMDA (Japan) and EDQM (Europe). Alivus Life Sciences is listed on BSE and NSE.

Learn more about Alivus Life Sciences Limited on https://www.alivus.com

For any further queries please contact:
Soumi Rao | Senior General Manager – Corporate Communications
Email: Soumi.Rao@alivus.com
Mobile: 98701 96931

Ernst & Young LLP – Investor Relations
Diwakar Pingle
Email: Diwakar.Pingle@in.ey.com

Sneha Salian
Email: Sneha2.Salian@in.ey.com